Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Immunogenicity of CR8020 in Healthy Japanese Subjects
NCT02015533Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Influenza A (IAV) comparing CR8020 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events up to 99 days. Planned start Dec 2013; status: withdrawn.
02
Drugs
CR8020
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02015533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015533.